You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:


Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,507,212

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,507,212
Title:Method for use of homopiperazinium compounds in the treatment of cancer
Abstract: A method for treating cancer including administering to a patient in need thereof an effective amount of a compound having the formula: ##STR00001## wherein R.sub.1, R.sub.2, Ya, Xa, and J.sup.- are as defined herein, and may be where R1 and R2 are independently selected from methyl, ethyl, n-propyl, or i-propyl; Xa is N or CH; Ya is hydrogen or independently selected from halogen, cyano, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, heteroaryl of 6 members and aryl; n is 1 or 2; wherein J.sup.- is fluoride, chloride, bromide, iodide, acetate, sulfate or sulfonate such as tosylate, mesylate, besylate.
Inventor(s): Cormier; Yvon (Quebec, CA), Israel-Assayag; Evelyne (Quebec, CA)
Assignee: UNIVERSITE LAVAL (Quebec, CA)
Application Number:15/921,138
Patent Claims:see list of patent claims

Details for Patent 10,507,212

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial UNIVERSITE LAVAL (Quebec, CA) 2034-04-03 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial UNIVERSITE LAVAL (Quebec, CA) 2034-04-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.